摘要
背景:非编码小RNA参与生物体的发育,其异常调控可引起包括肝细胞癌(HCC)在内的多种疾病,但其确切机制尚不清楚。目的:探讨miR-142-3p对肝细胞癌HMGB 1表达的影响。方法:采用RT-PCR方法检测肝癌组织和培养细胞中miR-142-3p的表达水平.采用Transwell迁移和侵袭试验检测HepG 2细胞的侵袭转移能力,Western印迹法检测其蛋白表达。结果:本研究报道miR-142-3p促进肝癌细胞的侵袭和迁移。MIR-142-3p在肝癌组织中的表达低于癌旁非癌组织,提示miR-142-3p具有抑癌作用。高迁移率盒蛋白1(HMGB 1)是一种促进肝癌转移的癌基因。单用MIR-142-3p或HMGB 1基因敲除可抑制肝癌细胞的侵袭和迁移,而HMGB 1过表达则阻碍miR-142-3p的作用。进一步的研究表明,HMGB 1是肝癌miR-142-3p的直接靶基因。MIR-142-3p通过直接结合HMGB 1的3‘非翻译区(UTR)来抑制HMGB 1基因的转录,从而抑制癌细胞的侵袭和迁移。结论:本研究首次报道miR-142-3p是一种通过直接调控HMGB 1基因转录而抑制肝癌细胞侵袭和迁移的新型抑癌基因。因此,miR-142-3p可能是肝癌患者潜在的诊断和治疗生物标志物。
关键词: 肝细胞癌,miR-142-3p,HMGB 1,迁移,侵袭,抑癌。
Current Molecular Medicine
Title:miR-142-3p Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Regulating HMGB1 Gene Expression
Volume: 18 Issue: 3
关键词: 肝细胞癌,miR-142-3p,HMGB 1,迁移,侵袭,抑癌。
摘要: Background: Non-coding small RNAs are involved in organism development, and their aberrant regulation induces various diseases, including hepatocellular carcinoma (HCC), but their exact mechanisms have not been determined.
Objective: The aim was to investigate the role of miR-142-3p on HMGB1 expression in hepatocellular carcinoma.
Methods: Expression levels of miR-142-3p in HCC tissues and cultured cells were measured by RT-PCR. The invasion and metastasis abilities of HepG2 cells according to Transwell migration and invasion assays, and protein expression was measured by western blotting.
Results: The present study reported that miR-142-3p promotes the invasion and migration of HCC cells. miR-142-3p levels are lower in HCC tissues than in adjacent non-cancerous tissues, suggesting a tumor suppressor role for miR-142-3p. Highmobility group box protein 1 (HMGB1) is an oncogene that promotes the metastasis of HCC. miR-142-3p or HMGB1 knockdown alone inhibits the invasion and migration of HCC cells, and HMGB1 overexpression impedes the effect of miR-142-3p. Further studies showed that HMGB1 is a direct target gene of miR-142-3p in HCC. miR-142-3p represses HMGB1 gene transcription by directly binding to the 3′ untranslated region (UTR) of HMGB1, thereby inhibiting cancer cell invasion and migration.
Conclusion: This study, for the first time, reports that miR-142-3p is a novel tumor suppressor that inhibits the invasion and migration of HCC cells by directly regulating gene transcription of HMGB1. Thus, miR-142-3p may be a potential diagnostic and therapeutic biomarker for HCC patients.
Export Options
About this article
Cite this article as:
miR-142-3p Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Regulating HMGB1 Gene Expression, Current Molecular Medicine 2018; 18 (3) . https://dx.doi.org/10.2174/1566524018666180907161124
DOI https://dx.doi.org/10.2174/1566524018666180907161124 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Use of Transgenic Mice as Models for Prostate Cancer Chemoprevention
Current Molecular Medicine The Expression Patterns and Clinical Significance of microRNAs in Liver Diseases and Hepatocellular Carcinoma
Current Pharmaceutical Design Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry Glycosylation of Tetraspanin Tspan-1 at Four Distinct Sites Promotes Its Transition Through the Endoplasmic Reticulum
Protein & Peptide Letters Cachexia and Herbal Medicine: Perspective
Current Pharmaceutical Design NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Curcumin as an Adjuvant to Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design Natural-based Hydrogels: A Journey from Simple to Smart Networks for Medical Examination
Current Medicinal Chemistry Anti-resorptive Drugs and their Impact on Maxillofacial Bone among Cancer Patients
Anti-Cancer Agents in Medicinal Chemistry Chemotherapy and Molecular Therapy in Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer
Current Cancer Drug Targets Cytochrome P450 Structure, Function and Clinical Significance: A Review
Current Drug Targets Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
Current Cancer Drug Targets Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: A Review on Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Advances of AKT Pathway in Human Oncogenesis and as a Target for Anti-Cancer Drug Discovery
Current Cancer Drug Targets Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer
Current Drug Discovery Technologies Anti-Galectin Compounds as Potential Anti-Cancer Drugs
Current Medicinal Chemistry